posaconazol mylan 100 mg
delorbis pharmaceuticals ltd - cipru - posaconazolum - compr. gastrorez. - 100mg - antimicotice de uz sistemic derivati de triazol
cegfila (previously pegfilgrastim mundipharma)
mundipharma corporation (ireland) limited - pegfilgrastimuluila - neutropenie - imunostimulante, - reducere durata de neutropenie şi incidenţa de neutropenie febrilă la pacienţii adulţi trataţi cu chimioterapie citotoxică pentru malignitate (cu excepția cronice myeloid leucemie şi mielodisplazice sindroame).
abacavir/lamivudina mylan pharma 600 mg/300 mg
mcdermott laboratories limited t/a - irlanda - abacavirum+lamivudinum - compr. film. - 600mg/300mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii
bortezomib biotech 3,5 mg
venus pharma gmbh - germania - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice inhibitori de proteazom
abacavir/lamivudina mylan pharma 600 mg/300 mg
mcdermott laboratories limited t/a - irlanda - abacavirum+lamivudinum - compr. film. - 600mg/300mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii
emtricitabina/tenofovir disoproxil accordpharma 200 mg/245 mg
pharmadox healthcare ltd - malta - combinatii (emtricitabinum+tenofovirum) - compr. film. - 200mg/245mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii
virbagen omega
virbac s.a. - recombinant omega interferon de origine felină - imunostimulante, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. la pisicile infectate cu fiv, mortalitatea a fost scăzută (5%) și nu a fost influențată de tratament.
bortezomib koanaa 3,5 mg
wave pharma limited - marea britanie - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice
tevocor 1000 mg
teva pharm. works private ltd. company - ungaria - acid omega-3-esteri etilici 90 - caps. moi - 1000 mg - hipocolesterolemiante si hipotrigliceridemiante alte hipocolesterolemiante si hipotrigliceridemiante
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenți antineoplazici - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.